
usd pm et
summari merck one world lead biopharmaceut compani well produc
vaccin anim health medic
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
revenu yoy
consensu due one-off declin
key papillomaviru vaccin gardasil
result shift manufactur suppli
revenu growth driven key oncolog
drug keytruda total sale yoy
offset double-digit declin gardasil
total sale yoy expect
recov start vaccin see strong
around yoy expect
continu growth key oncolog vaccin
hospit anim health segment also
acknowledg compani innov
pipelin anticip continu growth
keytruda sale make around total
revenu
welcom merck decis spin
first half women health legaci
biosimilar new compani
newco enabl faster growth
greater focu key growth driver base
estim newco amount
merck revenu sale
transact expect gener
oper effici non-gaap
oper margin greater
achiev view
expect see revenu growth
sustain demand keytruda
favor patent market exclus
period saw three
due gener biosimilar entri look
forward see favor patent setup
key brand lose market exclus
growth engin keytruda
patent
expect keytruda grow uptak
exist cancer indic like lung
melanoma kidney well potenti
longer term approv major indic
breast colon ketyruda
success pair stabl revenu
rest portfolio see healthi
runway ep growth despit
headwind due
target ep estim
in-lin forward price-to-earnings
averag expect neg impact
first three quarter first visibl
chines oper spread global
lower-than-expect market share
keytruda vaccin potenti new
 regul drug price
subject intens competit treatment
market share brand-nam drug also face
risk gener biosimilar maker market
copi brand challeng patent court
flood market patent expir also risk
associ drug failur clinic trial regulatori
approv hurdl potenti unfavor price
patent regul hand govern
risk balanc valuabl franchis
immuno-oncolog vaccin drug
experi persist demand due industri lead
apr ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
execut vice-president global
corpor overview merck co lead global drugmak produc wide rang
prescript drug vaccin mani therapeut area abroad largest
market account total revenu europ middl east africa second
largest
top-sel product includ keytruda cancer sale januvia/janumet type
hiv/aid bridion revers neuromuscular block agent pneumovax pneumococc
vaccin simponi arthritis/immunolog
addit human pharmaceut vaccin also anim health segment
sale anim health develop market pharmaceut vaccin product prevent
treatment control diseas major livestock companion anim speci
keytruda top-sel drug keytruda primari driver behind earn growth sinc
cancer drug first approv fda septemb second-lin treatment
first treatment option fail melanoma held long-stand strategi expand
indic keytruda lucr first-lin treatment set prescript
written cancer largest patient popul success
strategi ketyruda gain approv broad rang cancer indic sever
first-lin treatment set februari keytruda fda approv indic includ among
other first-lin treatment non-smal cell lung cancer nsclc combin chemotherapi
singl agent first-lin treatment nsclc patient specif tumor express second-lin
treatment head neck squamou cell cancer second-lin treatment cervic cancer
second-lin treatment hepatocellular liver cancer
keytruda gain first-lin nsclc indic due lung second-most common
type cancer achiev major mileston drug keytruda success indic
expans fuel tremend sale growth million billion
keytruda gain addit first-lin indic throughout fda european commiss
japanes ministri includ renal cell carcinoma kidney cancer head neck
cancer keytruda also on-going phase clinic trial mani type cancer like
continu drive robust growth sever year includ phase trial breast prostat
colorect cancer among top-fiv common type cancer behind lung
term frequenc
one drag keytruda futur sale growth outcom patent disput relat drug
biolog formul januari enter settlement licens agreement resolv
world-wide patent infring litig relat keytruda pursuant settlement compani
pay royalti net sale keytruda net sale keytruda
bristol-my squibb develop partner ono
market profil world-wide total prescript drug sale project grow compound annual
growth rate compound-annual-growth-rate period accord forecast evaluatepharma
key driver growth age develop popul especi babi
boomer age prime year health care need emerg market like see materi faster
growth prescript sale develop market howev due view
emerg market demand pharmaceut spur rise standard live global middl
class expand gain access advanc health care develop market govern
increas spend health care
financi trend total revenu grew billion billion three-year
compound-annual-growth-rate expens total billion sale sale
acquir new asset peloton clinical-stag biopharmaceut compani
purchas incur higher expens clinic earli drug develop
discoveri research adjust ep increas repres
three-year compound-annual-growth-rate key driver faster growth adjust ep revenu
share repurchas activ compani made net repurchas billion compar
decemb share repurchas author
remain howev coronaviru crisi start deepen late expect halt
compani share buy-back program believ conserv capit earn
interest tax amort depreci ebitda cover net interest expens roughli
time net debt/ebitda decemb
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
neutral sinc januari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook sub-industri
next year neutral expect
modest revenu growth driven
recent slowdown novel drug approv
potenti new industri price regul
neg partial off-set
upcom period low patent expir
also expect major gener maker continu
struggl due lower-cost emerg
follow banner year novel drug approv
fda signific
slowdown occur think
weigh drug maker revenu growth next
year novel brand drug enter market
gener competit often rival brand
either provid signific boost
revenu firm market
total number fda novel drug
approv fell versu
expect mean less revenu boost
major brand drug maker year ahead
estim sub-industri total
 spend pace
yoy declin septemb like
reflect effort maintain margin
sluggish revenu growth year ahead
addit fewer new brand enter
risk new price rule view
accord studi wall street
govern health system develop
countri like england norway canada
often pay less major drug
medicar kaiser famili foundat
poll indic american feel
drug cost unreason believ
dynam rais pressur drug maker
curtail usual price hike
politician enact polici lower
drug cost voter accordingli sever new
propos lower drug price emerg
side isl recent month
includ bill hous democrat
would allow medicar directli negoti
price drug maker senat
maximum medicar drug plan shift
cost burden drug maker
unclear new propos
enough support becom law see
polit parti increas focu
control drug cost signific risk
weigh outlook
balanc neg factor face
brand drug maker upcom period
low patent expir typic
biggest revenu headwind loss patent
protect open door gener
biosimilar competit base data
evaluatepharma annual global drug sale
risk expir patent averag
total forecast
drop fewer
patent cliff year ahead
major posit brand drug revenu
beyond brand firm make lion
share sub-industri market cap outlook
gener drug firm neg think
india-bas gener maker continu
take market share develop nation
firm due lower product cost
saw occur last year establish firm
like israel-bas teva saw sale
declin year-to-d thru sale
india-bas aurobindo sun pharma
grew yoy think due
rise broader composit
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
pm et cfra maintain buy opinion share merck co inc
lift price target ep
estim -- five-year forward price-to-earnings averag due acceler
growth rais ep estim
annual revenu growth averag period saw
three -- zetia remicad vytorin -- former top drug undergo major
sale declin due competit gener biosimilar entri drug
gener revenu look
forward see favor patent market exclus setup
expect annual revenu growth averag think
faster growth outlook compar previou five-year averag justifi
materi valuat premium five-year forward price-to-earnings averag /colin scarola
et cfra upgrad opinion share merck co inc buy
hold lift target
ep estim -- five-year forward price-to-earnings averag due acceler
growth organ sale growth best histori
yoy rapidli acceler full-year keytruda
revenu continu deliv sale yoy also note
rest portfolio stabil see sale declin
three year expect keytruda continu grow rapidli share gain
larg popul includ line lung cancer melanoma import
new indic includ april approv line kidney cancer
tremend growth potenti set backdrop stabl
revenu rest portfolio think ep growth averag
next three year versu valuat near
five-year averag despit acceler growth expect share
analyst research note compani news
pm et cfra maintain strong buy opinion share merck co
inc cut target base
price-to-earnings line mrk histor forward price-to-earnings
averag lower adj ep estim
adj ep estim expect increas
headwind crisi deepen expect neg impact
compani result first three quarter stem
mainli chines oper spread global start
mrk pharmaceut vaccin busi china fast
grow last year total revenu vs
increas import china overal result although remain
rel small compar main market total
maintain long-term posit outlook robust demand key
oncolog drug keytruda favor patent market exclus setup
expect short-term headwind relat shock /sel hardi
pm et cfra keep strong buy opinion share merck co inc
keep target ep estim
mrk forward price-to-earnings cut ep estim
impli ep growth yoy maintain
estim ep vs in-lin expect beat
consensu revenu yoy
consensu due one-off declin key human papillomaviru vaccin
gardasil result shift manufactur suppli revenu
growth driven key oncolog drug keytruda sale total sale
yoy offset double-digit declin gardasil total sale
yoy expect recov start vaccin continu see
strong global demand welcom merck decis spin-off
women health legaci brand biosimilar product new
compani base estim merck revenu
sale enabl faster growth greater focu key growth
et cfra rais opinion share merck co inc
strong buy buy lift target
ep estim -- forward price-to-earnings averag due
acceler growth rais ep estim
start ep vs yoy
beat consensu revenu adjust ep beat consensu estim
respect power lead drug keytruda cancer
sale saw sale increas yoy sinc approv
keytruda fast becom doctor standard care non-smal
cell lung cancer global market rapidli gain market
share outsid yoy intern growth addit
stretch neg growth ex-keytruda revenu
pace grow driven strong demand critic vaccin
continu think share under-valued base strong growth
trajectori rise oper leverag /colin scarola
et cfra maintain buy opinion share merck co inc
keep target price ep estim
-- histor forward price-to-earnings averag due acceler growth
rais ep estim ep
vs beat consensu revenu grew yoy
fastest growth sinc becom familiar lead cancer drug
keytruda sale led way yoy sale growth reach
annual drug continu gain momentum major indic
includ non-smal cell lung kidney cancer revenu growth also
benefit improv non-keytruda portfolio grew yoy
straight quarter declin due loss exclus former
key drug continu strong growth outlook due momentum
oncolog favor market exclus setup rest
portfolio think justifi materi valuat premium histor
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
